178 related articles for article (PubMed ID: 36064940)
21. Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization.
Gui B; Weiner AA; Nosher J; Lu SE; Foltz GM; Hasan O; Kim SK; Gendel V; Mani NB; Carpizo DR; Saad NE; Kennedy TJ; Zuckerman DA; Olsen JR; Parikh PJ; Jabbour SK
Am J Clin Oncol; 2018 Sep; 41(9):861-866. PubMed ID: 28418940
[TBL] [Abstract][Full Text] [Related]
22. Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma.
Hansmann J; Evers MJ; Bui JT; Lokken RP; Lipnik AJ; Gaba RC; Ray CE
J Vasc Interv Radiol; 2017 Sep; 28(9):1224-1231.e2. PubMed ID: 28688815
[TBL] [Abstract][Full Text] [Related]
23. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Hiraoka A; Kumada T; Kudo M; Hirooka M; Koizumi Y; Hiasa Y; Tajiri K; Toyoda H; Tada T; Ochi H; Joko K; Shimada N; Deguchi A; Ishikawa T; Imai M; Tsuji K; Michitaka K;
Dig Dis; 2017; 35(6):602-610. PubMed ID: 29040999
[TBL] [Abstract][Full Text] [Related]
24. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
[TBL] [Abstract][Full Text] [Related]
25. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
26. Survival Analysis Using Albumin-Bilirubin (ALBI) Grade for Patients Treated with Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma.
Young LB; Tabrizian P; Sung J; Biederman D; Bishay VL; Ranade M; Patel RS; Nowakowski FS; Fischman AM; Lookstein RA; Kim E
J Vasc Interv Radiol; 2022 May; 33(5):510-517.e1. PubMed ID: 35150838
[TBL] [Abstract][Full Text] [Related]
27. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
28. Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization.
Chen HY; Kee KM; Lu SN; Wang JH; Chen CH; Hung CH; Yen YH; Kuo YH
J Formos Med Assoc; 2022 Apr; 121(4):778-786. PubMed ID: 34303584
[TBL] [Abstract][Full Text] [Related]
29. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Ho SY; Hsu CY; Liu PH; Lee RC; Ko CC; Huang YH; Su CW; Hou MC; Huo TI
Dig Dis Sci; 2021 May; 66(5):1730-1738. PubMed ID: 32548811
[TBL] [Abstract][Full Text] [Related]
30. Quantification of Blood Pressure Changes in the Vascular Compartment When Using an Anti-Reflux Catheter during Chemoembolization versus Radioembolization: A Retrospective Case Series.
Rose SC; Narsinh KH; Newton IG
J Vasc Interv Radiol; 2017 Jan; 28(1):103-110. PubMed ID: 27840042
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.
Moreno-Luna LE; Yang JD; Sanchez W; Paz-Fumagalli R; Harnois DM; Mettler TA; Gansen DN; de Groen PC; Lazaridis KN; Narayanan Menon KV; Larusso NF; Alberts SR; Gores GJ; Fleming CJ; Slettedahl SW; Harmsen WS; Therneau TM; Wiseman GA; Andrews JC; Roberts LR
Cardiovasc Intervent Radiol; 2013 Jun; 36(3):714-23. PubMed ID: 23093355
[TBL] [Abstract][Full Text] [Related]
32. Survival and Toxicities after
Emmons EC; Bishay S; Du L; Krebs H; Gandhi RT; Collins ZS; O'Hara R; Akhter NM; Wang EA; Grilli C; Brower JS; Peck SR; Petroziello M; Abdel Aal AK; Golzarian J; Kennedy AS; Matsuoka L; Sze DY; Brown DB
Radiology; 2022 Oct; 305(1):228-236. PubMed ID: 35762890
[TBL] [Abstract][Full Text] [Related]
33. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
[TBL] [Abstract][Full Text] [Related]
34. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses.
Rognoni C; Ciani O; Sommariva S; Facciorusso A; Tarricone R; Bhoori S; Mazzaferro V
Oncotarget; 2016 Nov; 7(44):72343-72355. PubMed ID: 27579537
[TBL] [Abstract][Full Text] [Related]
35. Radioembolization for Intermediate-Stage Hepatocellular Carcinoma Maintains Liver Function and Permits Systemic Therapy at Progression.
Ranganathan S; Gabr A; Entezari P; Gordon AC; Riaz A; Desai K; Thornburg B; Kulik L; Kalyan A; Salem R; Lewandowski RJ
J Vasc Interv Radiol; 2023 Jun; 34(6):968-975. PubMed ID: 36791957
[TBL] [Abstract][Full Text] [Related]
36. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
Kallini JR; Gabr A; Salem R; Lewandowski RJ
Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
[TBL] [Abstract][Full Text] [Related]
37. Nomogram and Artificial Neural Network for Prognostic Performance on the Albumin-Bilirubin Grade for Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Zhong BY; Ni CF; Ji JS; Yin GW; Chen L; Zhu HD; Guo JH; He SC; Deng G; Zhang Q; Li PC; Yu H; Song JJ; Teng GJ
J Vasc Interv Radiol; 2019 Mar; 30(3):330-338. PubMed ID: 30819473
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization and radioembolization: a retrospective study.
Jeliazkova P; Umgelter A; Braren R; Kaissis G; Mustafa M; Einwächter H
Eur J Gastroenterol Hepatol; 2020 Aug; 32(8):1036-1041. PubMed ID: 31851090
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review.
Alonso JC; Casans I; González FM; Fuster D; Rodríguez A; Sánchez N; Oyagüez I; Burgos R; Williams AO; Espinoza N
BMC Gastroenterol; 2022 Jul; 22(1):326. PubMed ID: 35780112
[TBL] [Abstract][Full Text] [Related]
40. LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis.
Leyh C; Heucke N; Schotten C; Büchter M; Bechmann LP; Wichert M; Dechêne A; Herrmann K; Heider D; Sydor S; Lemmer P; Ludwig JM; Pospiech J; Theysohn J; Damm R; March C; Powerski M; Pech M; Özcürümez M; Weigt J; Keitel V; Lange CM; Schmidt H; Canbay A; Best J; Gerken G; Manka PP
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
